PT Interbat Competitors

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Kimia Farma merupakan pioner dalam industri farmasi Indonesia. Cikal bakal perusahaan dapat dirunut balik ke tahun 1917, ketika NV Chemicalien Handle Rathkamp & Co., perusahaan farmasi pertama di Hindia Timur, didirikan. Sejalan dengan kebijakan nasionalisasi eks perusahaan-perusahaan Belanda, pada tahun 1958 pemerintah melebur sejumlah perusahaan farmasi menjadi PNF Bhinneka Kimia Farma. Selanjutnya pada tanggal 16 Agustus 1971 bentuk hukumnya diubah menjadi Perseroan Terbatas, menjadi PT Kimia Farma (Persero). Sejak tanggal 4 Juli 2001 Kimia Farma tercatat sebagai perusahaan publik di Bursa Efek Jakarta dan Bursa Efek Surabaya. Berbekal tradisi industri yang panjang selama lebih dari 187 tahun dan nama yang identik dengan mutu, hari ini Kimia Farma telah berkembang menjadi sebuah perusahaan pelayanan kesehatan utama di Indonesia yang kian memainkan peranan penting dalam pengembangan dan pembangunan bangsa dan masyarakat.

PT Darya-Varia Laboratoria Tbk (“Darya-Varia”) was established in 1976 as a domestic investment pharmaceutical company. In November 1994, Darya-Varia listed its shares on the Indonesia Stock Exchange (IDX) with the stock ticker code of DVLA. Currently, Darya-Varia operates two manufacturing plants in Gunung Putri and Citeureup that have met the international standards of current Good Manufacturing Practice (c-GMP) and standards set by the National Agency of Drug and Food Control (BPOM). Darya-Varia always ensures the quality and safety of each product. All products of the Company are halal certified. All plant facilities owned by Darya-Varia have implemented the halal assurance system.